Table 7.
Health technology assessment information deemed to be important by stakeholders by stakeholder category (scale responses: 1 = strongly disagree; 7 = strongly agree)
| Decision-maker | Purchaser of services/pharma products | Professional service provider | Evidence generator | Advocate of health promotion | Total | Kruskal–Wallis test | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Statements | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | P value |
| Prevalence of smoking | 29 | 5.66 (2.01) | 7 | 6.71 (0.49) | 18 | 6.33 (1.28) | 25 | 5.84 (1.72) | 14 | 5.57 (1.70) | 93 | 5.90 (1.69) | 0.43 |
| Costs of smoking | 29 | 6.55 (0.83) | 7 | 6.71 (0.76) | 18 | 6.61 (0.78) | 25 | 6.36 (1.32) | 14 | 6.50 (0.65) | 93 | 6.52 (0.94) | 0.81 |
| Quality of life | 29 | 6.17 (0.85) | 7 | 6.14 (1.22) | 18 | 5.61 (1.58) | 25 | 5.64 (1.66) | 14 | 5.64 (1.69) | 93 | 5.84 (1.40) | 0.76 |
| Mortality due to smoking | 29 | 6.59 (0.98) | 7 | 6.57 (0.79) | 18 | 6.33 (1.03) | 25 | 6.20 (1.50) | 14 | 5.71 (2.09) | 93 | 6.30 (1.35) | 0.68 |
| Effectiveness of smoking cessation interventions (such as quit and relapse rates) | 29 | 6.59 (0.83) | 7 | 6.71 (0.76) | 18 | 6.56 (1.20) | 25 | 6.12 (1.76) | 14 | 6.29 (1.59) | 93 | 6.42 (1.31) | 0.76 |
| Cost-effectiveness data comparing the cost of smoking cessation interventions with its health and wider benefits | 29 | 6.66 (0.48) | 7 | 6.86 (0.38) | 18 | 6.33 (0.97) | 25 | 6.52 (0.82) | 14 | 6.57 (0.85) | 93 | 6.56 (0.74) | 0.65 |
| Budget impact reflecting financial outcomes specifically at organisational level | 29 | 6.17 (1.39) | 7 | 6.57 (0.56) | 18 | 6.33 (0.97) | 25 | 6.20 (1.19) | 14 | 6.36 (0.93) | 93 | 6.27 (1.13) | 0.99 |
SD, Standard deviation